PrimeGene a biotechne brand

Recombinant Human DES1-3 Insulin-like Growth Factor 1 (rHuDES1-3 IGF-1)

PrimeGene Technical Data Sheet

Source:Escherichia coli.Molecular Weight:Approximately 7.4 kDa, a single non-glycosylated polypeptide chain containing 67 amino acids.Quantity:20µg/100µg/1000µgAA Sequence:TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSAPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 10 ⁵ IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.Endotoxin:Ke recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.Shipping:The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature.
Quantity: $20\mu g/100\mu g/1000\mu g$ AA Sequence:TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSAPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 10 ⁵ IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be made in appropriate buffered solutions.
AA Sequence:TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSAPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0×10^5 IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
LKPAKSAPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0×10^5 IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
Purity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 10 ⁵ IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Biological Activity:Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0×10^5 IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder. Lyophilized from a 0.2μ m filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0×10^5 IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a $0.2 \mu m$ filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
of > 5.0×10^5 IU/mg.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a $0.2 \ \mu m$ filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than $50 \ EU/mg$ of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing $0.1 \ \%$ BSA to a concentration of 0.1 -1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at $\leq -20 \ \%$ C. Further dilutions should be made in appropriate buffered solutions.
Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Formulation:Lyophilized from a 0.2 μ m filtered concentrated solution in PBS, pH 7.4.Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
Endotoxin:Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
Shipping . The product is shipped at ambient temperature. Upon receipt store it immediately at the temperature
recommended below.
Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• 12 months from date of receipt, -20 to -70 °C as supplied.
• 1 month, 2 to 8 °C under sterile conditions after reconstitution.
• 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Usage: This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further
evaluation purposes. NOT FOR HUMAN USE .

Human DES1-3 Insulin-like Growth Factor 1

IGF-1 belonged to the insulin gene family, is a mitogenic polypeptide growth factor that stimulates the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. DES(1-3)IGF-1, is a truncated variant of human IGF-1 with the tripeptide Gly-Pro-Glu absent from the N-terminus. It has been isolated from bovine colostrum, human brain and porcine uterus. The DES(1-3)IGF-1 probably results from post-translational cleavage of IGF-1. It has about 10-fold more potent than IGF-I at stimulating hypertrophy and proliferation of cultured cells, a consequence of much reduced binding to IGF-binding proteins, in turn caused by the absence of the glutamate at position 3. Clinical opportunities for DES(1-3)IGF-1 have not yet been evaluated, but could apply in catabolic states as well as for the treatment of inflammatory bowel diseases.

Website: www.primegene.com Fax: +86 21 61077348